HDL Therapeutics
Vero Beach
About HDL Therapeutics
HDL Therapeutics have developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.8M
- Funding stage: Late Stage Venture
- Last round: Series E (Mar 2021)
- Website: hdltherapeutics.com
- Phone: (772) 453-2770
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hdl-therapeutics-3238 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.